FSD Pharma Inc. (NASDAQ: HUGE) Stock Competitors & Peer Comparison
See HUGE's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HUGE and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HUGE | $0.09 | -10.10% | 66.7K | -0.01 | -$16.25 | N/A |
| TAK | $17.24 | +2.50% | 54.9B | 12.41 | $1.39 | +3.65% |
| HLN | $9.78 | +0.72% | 43.1B | 24.49 | $0.40 | +1.97% |
| TEVA | $30.81 | -1.19% | 35.9B | 10.52 | $2.93 | N/A |
| VTRS | $17.24 | -0.23% | 20.1B | 7.04 | $2.45 | +2.77% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.91 | +0.52% | 12.4B | 25.41 | $0.98 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $11.79 | -0.08% | 9.8B | 19.35 | $0.61 | +0.54% |
| LNTH | $104.82 | +1.05% | 6.8B | 17.56 | $5.97 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
HUGE vs TAK Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, TAK has a market cap of 54.9B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while TAK trades at $17.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas TAK's P/E ratio is 12.41. In terms of profitability, HUGE's ROE is -0.85%, compared to TAK's ROE of +0.03%. Regarding short-term risk, HUGE is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check TAK's competition here
Haleon plc (NYSE: HLN)
HUGE vs HLN Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, HLN has a market cap of 43.1B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while HLN trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas HLN's P/E ratio is 24.49. In terms of profitability, HUGE's ROE is -0.85%, compared to HLN's ROE of +0.13%. Regarding short-term risk, HUGE is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
HUGE vs TEVA Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, TEVA has a market cap of 35.9B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while TEVA trades at $30.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas TEVA's P/E ratio is 10.52. In terms of profitability, HUGE's ROE is -0.85%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, HUGE is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
HUGE vs VTRS Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, VTRS has a market cap of 20.1B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while VTRS trades at $17.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas VTRS's P/E ratio is 7.04. In terms of profitability, HUGE's ROE is -0.85%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, HUGE is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
HUGE vs ITCI Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ITCI's P/E ratio is -180.64. In terms of profitability, HUGE's ROE is -0.85%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, HUGE is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
HUGE vs ELAN Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ELAN has a market cap of 12.4B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ELAN trades at $24.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ELAN's P/E ratio is 25.41. In terms of profitability, HUGE's ROE is -0.85%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, HUGE is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
HUGE vs CTLT Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas CTLT's P/E ratio is -27.84. In terms of profitability, HUGE's ROE is -0.85%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, HUGE is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
HUGE vs RDY Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, RDY has a market cap of 9.8B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while RDY trades at $11.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas RDY's P/E ratio is 19.35. In terms of profitability, HUGE's ROE is -0.85%, compared to RDY's ROE of +0.09%. Regarding short-term risk, HUGE is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
HUGE vs LNTH Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, LNTH has a market cap of 6.8B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while LNTH trades at $104.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas LNTH's P/E ratio is 17.56. In terms of profitability, HUGE's ROE is -0.85%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, HUGE is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
HUGE vs AMRX Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, AMRX has a market cap of 5.7B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while AMRX trades at $17.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas AMRX's P/E ratio is 19.91. In terms of profitability, HUGE's ROE is -0.85%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, HUGE is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
HUGE vs INDV Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, INDV has a market cap of 5.1B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while INDV trades at $40.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas INDV's P/E ratio is 13.46. In terms of profitability, HUGE's ROE is -0.85%, compared to INDV's ROE of -1.42%. Regarding short-term risk, HUGE is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
HUGE vs RGC Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, RGC has a market cap of 2.8B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while RGC trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas RGC's P/E ratio is -402.82. In terms of profitability, HUGE's ROE is -0.85%, compared to RGC's ROE of -2.32%. Regarding short-term risk, HUGE is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
HUGE vs SUPN Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while SUPN trades at $46.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas SUPN's P/E ratio is 13.47. In terms of profitability, HUGE's ROE is -0.85%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, HUGE is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check SUPN's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
HUGE vs DCPH Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas DCPH's P/E ratio is -11.58. In terms of profitability, HUGE's ROE is -0.85%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, HUGE is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
HUGE vs AVDL Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, HUGE's ROE is -0.85%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, HUGE is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check AVDL's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
HUGE vs HCM Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, HCM has a market cap of 1.9B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while HCM trades at $11.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas HCM's P/E ratio is 4.13. In terms of profitability, HUGE's ROE is -0.85%, compared to HCM's ROE of +0.37%. Regarding short-term risk, HUGE is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check HCM's competition here
Embecta Corp. (NASDAQ: EMBCV)
HUGE vs EMBCV Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas EMBCV's P/E ratio is N/A. In terms of profitability, HUGE's ROE is -0.85%, compared to EMBCV's ROE of -0.23%. Regarding short-term risk, HUGE is more volatile compared to EMBCV. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
HUGE vs DVAX Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas DVAX's P/E ratio is -41.89. In terms of profitability, HUGE's ROE is -0.85%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, HUGE is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
HUGE vs ANIP Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ANIP trades at $77.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ANIP's P/E ratio is 9.45. In terms of profitability, HUGE's ROE is -0.85%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, HUGE is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ANIP's competition here
Bausch Health Companies Inc. (NYSE: BHC)
HUGE vs BHC Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, BHC has a market cap of 1.7B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while BHC trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas BHC's P/E ratio is 1.13. In terms of profitability, HUGE's ROE is -0.85%, compared to BHC's ROE of +1.21%. Regarding short-term risk, HUGE is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check BHC's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
HUGE vs TARO Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas TARO's P/E ratio is 30.05. In terms of profitability, HUGE's ROE is -0.85%, compared to TARO's ROE of +0.03%. Regarding short-term risk, HUGE is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
HUGE vs HROW Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while HROW trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas HROW's P/E ratio is 427.22. In terms of profitability, HUGE's ROE is -0.85%, compared to HROW's ROE of -0.34%. Regarding short-term risk, HUGE is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check HROW's competition here
Perrigo Company plc (NYSE: PRGO)
HUGE vs PRGO Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, PRGO has a market cap of 1.4B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while PRGO trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas PRGO's P/E ratio is 3.93. In terms of profitability, HUGE's ROE is -0.85%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, HUGE is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check PRGO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
HUGE vs PAHC Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while PAHC trades at $34.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas PAHC's P/E ratio is 11.62. In terms of profitability, HUGE's ROE is -0.85%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, HUGE is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check PAHC's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
HUGE vs ETON Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ETON trades at $42.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ETON's P/E ratio is -608.43. In terms of profitability, HUGE's ROE is -0.85%, compared to ETON's ROE of -0.06%. Regarding short-term risk, HUGE is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ETON's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
HUGE vs COLL Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, COLL has a market cap of 1.1B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while COLL trades at $35.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas COLL's P/E ratio is 4.55. In terms of profitability, HUGE's ROE is -0.85%, compared to COLL's ROE of +0.27%. Regarding short-term risk, HUGE is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check COLL's competition here
Cronos Group Inc. (NASDAQ: CRON)
HUGE vs CRON Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, CRON has a market cap of 1B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while CRON trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas CRON's P/E ratio is -113.77. In terms of profitability, HUGE's ROE is -0.85%, compared to CRON's ROE of -0.00%. Regarding short-term risk, HUGE is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check CRON's competition here
Alvotech (NASDAQ: ALVO)
HUGE vs ALVO Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ALVO has a market cap of 1B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ALVO trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ALVO's P/E ratio is -9.00. In terms of profitability, HUGE's ROE is -0.85%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, HUGE is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ALVO's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
HUGE vs PCRX Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while PCRX trades at $25.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas PCRX's P/E ratio is 9.92. In terms of profitability, HUGE's ROE is -0.85%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, HUGE is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
HUGE vs PETQ Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas PETQ's P/E ratio is 83.73. In terms of profitability, HUGE's ROE is -0.85%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, HUGE is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check PETQ's competition here
Alvotech (NASDAQ: ALVOW)
HUGE vs ALVOW Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ALVOW has a market cap of 874.3M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ALVOW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ALVOW's P/E ratio is 21.87. In terms of profitability, HUGE's ROE is -0.85%, compared to ALVOW's ROE of +0.35%. Regarding short-term risk, HUGE is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ALVOW's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
HUGE vs AMPH Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, AMPH has a market cap of 825.4M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while AMPH trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas AMPH's P/E ratio is 6.39. In terms of profitability, HUGE's ROE is -0.85%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, HUGE is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check AMPH's competition here
Evotec SE (NASDAQ: EVO)
HUGE vs EVO Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, EVO has a market cap of 689.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while EVO trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas EVO's P/E ratio is -2.74. In terms of profitability, HUGE's ROE is -0.85%, compared to EVO's ROE of -0.24%. Regarding short-term risk, HUGE is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
HUGE vs IRWD Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, IRWD has a market cap of 610.7M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while IRWD trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas IRWD's P/E ratio is 6.08. In terms of profitability, HUGE's ROE is -0.85%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, HUGE is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
HUGE vs BDSI Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas BDSI's P/E ratio is 6.82. In terms of profitability, HUGE's ROE is -0.85%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, HUGE is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
HUGE vs TLRY Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, TLRY has a market cap of 465.6M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while TLRY trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas TLRY's P/E ratio is -6.12. In terms of profitability, HUGE's ROE is -0.85%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, HUGE is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
HUGE vs KMDA Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, KMDA has a market cap of 407.3M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while KMDA trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas KMDA's P/E ratio is 20.17. In terms of profitability, HUGE's ROE is -0.85%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, HUGE is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check KMDA's competition here
Evolus, Inc. (NASDAQ: EOLS)
HUGE vs EOLS Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, EOLS has a market cap of 393.8M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while EOLS trades at $5.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas EOLS's P/E ratio is -13.72. In terms of profitability, HUGE's ROE is -0.85%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, HUGE is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check EOLS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
HUGE vs CGC Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, CGC has a market cap of 375.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while CGC trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas CGC's P/E ratio is -0.53. In terms of profitability, HUGE's ROE is -0.85%, compared to CGC's ROE of -0.39%. Regarding short-term risk, HUGE is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check CGC's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
HUGE vs AQST Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, AQST has a market cap of 365.4M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while AQST trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas AQST's P/E ratio is -6.03. In terms of profitability, HUGE's ROE is -0.85%, compared to AQST's ROE of +1.91%. Regarding short-term risk, HUGE is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check AQST's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
HUGE vs ORGO Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ORGO has a market cap of 307.5M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ORGO trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ORGO's P/E ratio is 79.67. In terms of profitability, HUGE's ROE is -0.85%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, HUGE is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ORGO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
HUGE vs ALIM Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ALIM's P/E ratio is 5.28. In terms of profitability, HUGE's ROE is -0.85%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, HUGE is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ALIM's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
HUGE vs TKNO Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, TKNO has a market cap of 266.5M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while TKNO trades at $4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas TKNO's P/E ratio is -15.53. In terms of profitability, HUGE's ROE is -0.85%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, HUGE is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check TKNO's competition here
Landec Corporation (NASDAQ: LNDC)
HUGE vs LNDC Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas LNDC's P/E ratio is -4.04. In terms of profitability, HUGE's ROE is -0.85%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, HUGE is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check LNDC's competition here
Shineco, Inc. (NASDAQ: TYHT)
HUGE vs TYHT Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas TYHT's P/E ratio is -1.61. In terms of profitability, HUGE's ROE is -0.85%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, HUGE is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
HUGE vs SIGA Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, SIGA has a market cap of 223.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while SIGA trades at $3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas SIGA's P/E ratio is 11.52. In terms of profitability, HUGE's ROE is -0.85%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, HUGE is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check SIGA's competition here
Embecta Corp. (NASDAQ: EMBC)
HUGE vs EMBC Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, EMBC has a market cap of 195.2M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while EMBC trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas EMBC's P/E ratio is 1.27. In terms of profitability, HUGE's ROE is -0.85%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, HUGE is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check EMBC's competition here
Journey Medical Corporation (NASDAQ: DERM)
HUGE vs DERM Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, DERM has a market cap of 181.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while DERM trades at $6.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas DERM's P/E ratio is -17.78. In terms of profitability, HUGE's ROE is -0.85%, compared to DERM's ROE of -0.36%. Regarding short-term risk, HUGE is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check DERM's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
HUGE vs REPH Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas REPH's P/E ratio is -8.04. In terms of profitability, HUGE's ROE is -0.85%, compared to REPH's ROE of -0.22%. Regarding short-term risk, HUGE is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check REPH's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
HUGE vs ACB Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ACB has a market cap of 165.4M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ACB trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ACB's P/E ratio is 44.50. In terms of profitability, HUGE's ROE is -0.85%, compared to ACB's ROE of -0.14%. Regarding short-term risk, HUGE is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ACB's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
HUGE vs LFCR Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, LFCR has a market cap of 162.4M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while LFCR trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas LFCR's P/E ratio is -4.42. In terms of profitability, HUGE's ROE is -0.85%, compared to LFCR's ROE of -1.76%. Regarding short-term risk, HUGE is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
HUGE vs THTX Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas THTX's P/E ratio is -28.83. In terms of profitability, HUGE's ROE is -0.85%, compared to THTX's ROE of +0.17%. Regarding short-term risk, HUGE is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
HUGE vs ASRT Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ASRT's P/E ratio is -7.10. In terms of profitability, HUGE's ROE is -0.85%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, HUGE is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ASRT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
HUGE vs CRDL Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, CRDL has a market cap of 136M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while CRDL trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas CRDL's P/E ratio is -4.20. In terms of profitability, HUGE's ROE is -0.85%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, HUGE is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
HUGE vs OGI Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, OGI has a market cap of 131.6M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while OGI trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas OGI's P/E ratio is -3.59. In terms of profitability, HUGE's ROE is -0.85%, compared to OGI's ROE of -0.07%. Regarding short-term risk, HUGE is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check OGI's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
HUGE vs SCTL Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas SCTL's P/E ratio is -7.86. In terms of profitability, HUGE's ROE is -0.85%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, HUGE is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
HUGE vs PROC Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas PROC's P/E ratio is 1.53. In terms of profitability, HUGE's ROE is -0.85%, compared to PROC's ROE of -2.22%. Regarding short-term risk, HUGE is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
HUGE vs CPIX Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, CPIX has a market cap of 99M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while CPIX trades at $6.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas CPIX's P/E ratio is -36.72. In terms of profitability, HUGE's ROE is -0.85%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, HUGE is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
HUGE vs OPTN Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas OPTN's P/E ratio is -4.42. In terms of profitability, HUGE's ROE is -0.85%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, HUGE is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
HUGE vs ZOM Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ZOM's P/E ratio is -1.62. In terms of profitability, HUGE's ROE is -0.85%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, HUGE is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
HUGE vs GRVI Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas GRVI's P/E ratio is 26.05. In terms of profitability, HUGE's ROE is -0.85%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, HUGE is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
HUGE vs ZYBT Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ZYBT has a market cap of 80.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ZYBT trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ZYBT's P/E ratio is -7.68. In terms of profitability, HUGE's ROE is -0.85%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, HUGE is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
HUGE vs ZYNE Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, HUGE's ROE is -0.85%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, HUGE is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
HUGE vs SSIC Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas SSIC's P/E ratio is 11.93. In terms of profitability, HUGE's ROE is -0.85%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, HUGE is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
HUGE vs VLNS Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas VLNS's P/E ratio is -1.03. In terms of profitability, HUGE's ROE is -0.85%, compared to VLNS's ROE of N/A. Regarding short-term risk, HUGE is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
HUGE vs DRRX Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas DRRX's P/E ratio is -4.44. In terms of profitability, HUGE's ROE is -0.85%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, HUGE is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check DRRX's competition here
BGM Group Ltd. (NASDAQ: BGM)
HUGE vs BGM Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, BGM has a market cap of 58.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while BGM trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas BGM's P/E ratio is -1.00. In terms of profitability, HUGE's ROE is -0.85%, compared to BGM's ROE of -0.03%. Regarding short-term risk, HUGE is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check BGM's competition here
InterCure Ltd. (NASDAQ: INCR)
HUGE vs INCR Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, INCR has a market cap of 55.2M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while INCR trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas INCR's P/E ratio is -2.23. In terms of profitability, HUGE's ROE is -0.85%, compared to INCR's ROE of -0.09%. Regarding short-term risk, HUGE is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
HUGE vs JUPW Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas JUPW's P/E ratio is -2.41. In terms of profitability, HUGE's ROE is -0.85%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, HUGE is more volatile compared to JUPW. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
HUGE vs QLI Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas QLI's P/E ratio is -4.92. In terms of profitability, HUGE's ROE is -0.85%, compared to QLI's ROE of -0.16%. Regarding short-term risk, HUGE is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check QLI's competition here
Incannex Healthcare Limited (NASDAQ: IXHL)
HUGE vs IXHL Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, IXHL has a market cap of 35.3M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while IXHL trades at $2.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas IXHL's P/E ratio is -4.31. In terms of profitability, HUGE's ROE is -0.85%, compared to IXHL's ROE of -0.92%. Regarding short-term risk, HUGE is more volatile compared to IXHL. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check IXHL's competition here
HEXO Corp. (NASDAQ: HEXO)
HUGE vs HEXO Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas HEXO's P/E ratio is -0.26. In terms of profitability, HUGE's ROE is -0.85%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, HUGE is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check HEXO's competition here
Talphera, Inc. (NASDAQ: TLPH)
HUGE vs TLPH Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, TLPH has a market cap of 27.7M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while TLPH trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas TLPH's P/E ratio is -4.35. In terms of profitability, HUGE's ROE is -0.85%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, HUGE is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check TLPH's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
HUGE vs RMTI Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, RMTI has a market cap of 26.2M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while RMTI trades at $6.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas RMTI's P/E ratio is -6.31. In terms of profitability, HUGE's ROE is -0.85%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, HUGE is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check RMTI's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
HUGE vs TXMD Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, TXMD has a market cap of 23.8M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while TXMD trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas TXMD's P/E ratio is 104.94. In terms of profitability, HUGE's ROE is -0.85%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, HUGE is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
HUGE vs CYTH Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas CYTH's P/E ratio is -0.80. In terms of profitability, HUGE's ROE is -0.85%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, HUGE is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
HUGE vs EVOK Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas EVOK's P/E ratio is -7.97. In terms of profitability, HUGE's ROE is -0.85%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, HUGE is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check EVOK's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
HUGE vs AYTU Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, AYTU has a market cap of 17.5M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while AYTU trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas AYTU's P/E ratio is -1.13. In terms of profitability, HUGE's ROE is -0.85%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, HUGE is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check AYTU's competition here
Optimi Health Corp. (NASDAQ: OPTH)
HUGE vs OPTH Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while OPTH trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas OPTH's P/E ratio is -17.38. In terms of profitability, HUGE's ROE is -0.85%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, HUGE is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
HUGE vs ACRX Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ACRX's P/E ratio is -0.31. In terms of profitability, HUGE's ROE is -0.85%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, HUGE is more volatile compared to ACRX. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
HUGE vs BFRIW Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, BFRIW has a market cap of 13.5M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while BFRIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, HUGE's ROE is -0.85%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, HUGE is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
HUGE vs COSM Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, COSM has a market cap of 12.4M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while COSM trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas COSM's P/E ratio is -0.32. In terms of profitability, HUGE's ROE is -0.85%, compared to COSM's ROE of -0.96%. Regarding short-term risk, HUGE is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
HUGE vs AGRX Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas AGRX's P/E ratio is -0.89. In terms of profitability, HUGE's ROE is -0.85%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, HUGE is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check AGRX's competition here
Apimeds Pharmaceuticals US, Inc (AMEX: APUS)
HUGE vs APUS Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, APUS has a market cap of 8.5M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while APUS trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas APUS's P/E ratio is -2.08. In terms of profitability, HUGE's ROE is -0.85%, compared to APUS's ROE of -0.55%. Regarding short-term risk, HUGE is less volatile compared to APUS. This indicates lower risk in terms of short-term price fluctuations for HUGE.Check APUS's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
HUGE vs NLTX Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas NLTX's P/E ratio is -0.28. In terms of profitability, HUGE's ROE is -0.85%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, HUGE is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
HUGE vs LCI Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas LCI's P/E ratio is -0.04. In terms of profitability, HUGE's ROE is -0.85%, compared to LCI's ROE of +1.66%. Regarding short-term risk, HUGE is more volatile compared to LCI. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
HUGE vs ADMP Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ADMP's P/E ratio is -0.08. In terms of profitability, HUGE's ROE is -0.85%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, HUGE is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
HUGE vs GELS Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, GELS has a market cap of 6.4M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while GELS trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas GELS's P/E ratio is -1.40. In terms of profitability, HUGE's ROE is -0.85%, compared to GELS's ROE of -0.25%. Regarding short-term risk, HUGE is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
HUGE vs YCBD Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, YCBD has a market cap of 5.6M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while YCBD trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas YCBD's P/E ratio is -1.31. In terms of profitability, HUGE's ROE is -0.85%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, HUGE is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check YCBD's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
HUGE vs CPHI Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, CPHI has a market cap of 5.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while CPHI trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas CPHI's P/E ratio is -2.48. In terms of profitability, HUGE's ROE is -0.85%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, HUGE is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check CPHI's competition here
Mallinckrodt plc (AMEX: MNK)
HUGE vs MNK Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas MNK's P/E ratio is -0.44. In terms of profitability, HUGE's ROE is -0.85%, compared to MNK's ROE of -0.26%. Regarding short-term risk, HUGE is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for HUGE.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
HUGE vs FLGC Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas FLGC's P/E ratio is -0.19. In terms of profitability, HUGE's ROE is -0.85%, compared to FLGC's ROE of -2.70%. Regarding short-term risk, HUGE is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for HUGE.Check FLGC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
HUGE vs PLXP Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas PLXP's P/E ratio is -0.22. In terms of profitability, HUGE's ROE is -0.85%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, HUGE is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for HUGE.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
HUGE vs ATNX Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas ATNX's P/E ratio is -0.02. In terms of profitability, HUGE's ROE is -0.85%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, HUGE is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check ATNX's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
HUGE vs UPC Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, UPC has a market cap of 2.1M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while UPC trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas UPC's P/E ratio is -0.42. In terms of profitability, HUGE's ROE is -0.85%, compared to UPC's ROE of -0.07%. Regarding short-term risk, HUGE is more volatile compared to UPC. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check UPC's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
HUGE vs RDHL Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, RDHL has a market cap of 2M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while RDHL trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas RDHL's P/E ratio is 0.13. In terms of profitability, HUGE's ROE is -0.85%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, HUGE is more volatile compared to RDHL. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check RDHL's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
HUGE vs PROCW Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas PROCW's P/E ratio is N/A. In terms of profitability, HUGE's ROE is -0.85%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, HUGE is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check PROCW's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
HUGE vs SNOA Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, SNOA has a market cap of 1.9M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while SNOA trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas SNOA's P/E ratio is -1.21. In terms of profitability, HUGE's ROE is -0.85%, compared to SNOA's ROE of -0.88%. Regarding short-term risk, HUGE is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
HUGE vs SHPH Comparison July 2026
FSD Pharma Inc. (NASDAQ: HUGE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUGE stands at 66.7K. In comparison, SHPH has a market cap of 1.7M. Regarding current trading prices, HUGE is priced at $0.09 on the NASDAQ, while SHPH trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUGE currently has a P/E ratio of -0.01, whereas SHPH's P/E ratio is -0.13. In terms of profitability, HUGE's ROE is -0.85%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, HUGE is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for HUGE.Check SHPH's competition here